(Total Views: 475)
Posted On: 05/22/2025 9:04:01 AM
Post# of 154115
The following AI response helped me understand the second LL MoA.
Leronlimab is a chimeric monoclonal antibody that targets CXCR4, a protein expressed on the surface of myeloid-derived suppressor cells (MDSCs), T regulatory cells (Tregs), and some tumor cells. By blocking CXCR4, Leronlimab interferes with the ability of these immune suppressive cells to migrate into the tumor microenvironment and suppress the immune response. This reduces the immunosuppressive environment, allowing for a more effective anti-tumor immune response.
Here's a more detailed explanation:
Leronlimab targets CXCR4:
Leronlimab binds to CXCR4, a receptor that is expressed on various immunosuppressive cells, including MDSCs, Tregs, and some tumor cells.
CXCR4 is involved in migration:
CXCR4 plays a role in the migration of immune cells, including MDSCs and Tregs, into the tumor microenvironment.
MDSCs and Tregs suppress the immune response:
MDSCs and Tregs are known to suppress anti-tumor immune responses by various mechanisms, such as inhibiting T cell activation and proliferation.
Leronlimab reduces immunosuppression:
By blocking CXCR4, Leronlimab interferes with the migration of MDSCs and Tregs into the tumor microenvironment, reducing the immunosuppressive environment.
Enhanced anti-tumor immunity:
With a less immunosuppressive environment, the immune system can be more effective at targeting and eliminating tumor cells.
Improved treatment outcomes:
By targeting CXCR4 and reducing the immunosuppressive influence of MDSCs and Tregs, Leronlimab can potentially improve treatment outcomes for cancers.
The LL improved tumor micro environment in turn then helps induce a more robust and lethal Immune Checkpoint Inhibitor (ICI) response to the tumor cells.
Leronlimab is a chimeric monoclonal antibody that targets CXCR4, a protein expressed on the surface of myeloid-derived suppressor cells (MDSCs), T regulatory cells (Tregs), and some tumor cells. By blocking CXCR4, Leronlimab interferes with the ability of these immune suppressive cells to migrate into the tumor microenvironment and suppress the immune response. This reduces the immunosuppressive environment, allowing for a more effective anti-tumor immune response.
Here's a more detailed explanation:
Leronlimab targets CXCR4:
Leronlimab binds to CXCR4, a receptor that is expressed on various immunosuppressive cells, including MDSCs, Tregs, and some tumor cells.
CXCR4 is involved in migration:
CXCR4 plays a role in the migration of immune cells, including MDSCs and Tregs, into the tumor microenvironment.
MDSCs and Tregs suppress the immune response:
MDSCs and Tregs are known to suppress anti-tumor immune responses by various mechanisms, such as inhibiting T cell activation and proliferation.
Leronlimab reduces immunosuppression:
By blocking CXCR4, Leronlimab interferes with the migration of MDSCs and Tregs into the tumor microenvironment, reducing the immunosuppressive environment.
Enhanced anti-tumor immunity:
With a less immunosuppressive environment, the immune system can be more effective at targeting and eliminating tumor cells.
Improved treatment outcomes:
By targeting CXCR4 and reducing the immunosuppressive influence of MDSCs and Tregs, Leronlimab can potentially improve treatment outcomes for cancers.
The LL improved tumor micro environment in turn then helps induce a more robust and lethal Immune Checkpoint Inhibitor (ICI) response to the tumor cells.
(6)
(0)
